All Stories

  1. Targeting m6A-SCG2-TAMs axis overcomes 5-FU resistance in colorectal cancer via a multi-omics model
  2. Microvesicle release drives cycles of mitophagy flux disruption and inflammatory amplification in sepsis-induced myocardial dysfunction
  3. Evolution of CRISPR-enabled biosensors for amplification-free nucleic acid detection
  4. Bioinspired and biomimetic cancer-cell-derived membrane nanovesicles for preclinical tumor-targeted nanotheranostics
  5. Intratumoural Delivery of mRNA Loaded on a Cationic Hyper-Branched Cyclodextrin-Based Polymer Induced an Anti-Tumour Immunological Response in Melanoma
  6. Engineered Liposomes in Interventional Theranostics of Solid Tumors
  7. A receptor-mediated landscape of druggable and targeted nanomaterials for gliomas
  8. Bioengineered exosomal-membrane-camouflaged abiotic nanocarriers: neurodegenerative diseases, tissue engineering and regenerative medicine
  9. Hydrogels for RNA delivery
  10. mRNA therapy at the convergence of genetics and nanomedicine
  11. Biopolymeric Coatings for Local Release of Therapeutics from Biomedical Implants
  12. Technological challenges of biomembrane-coated top-down cancer nanotherapy
  13. ‘Passive’ nanoparticles for organ-selective systemic delivery: design, mechanism and perspective
  14. Using gold nanobeacons as a theranostic technique to recognize, detect, and inhibit specific nucleic acids
  15. Nucleic acid-based therapy for brain cancer: Challenges and strategies
  16. Magnetite and bismuth sulfide Janus heterostructures as radiosensitizers for in vivo enhanced radiotherapy in breast cancer
  17. Gold Nanoconjugates for miRNA Modulation in Cancer Therapy: From miRNA Silencing to miRNA Mimics
  18. The global burden of cancer attributable to risk factors, 2010–19: a systematic analysis for the Global Burden of Disease Study 2019
  19. Macrophage Cell Membrane‐Cloaked Nanoplatforms for Biomedical Applications
  20. Nanodelivery of nucleic acids
  21. Global, regional, and national burden of colorectal cancer and its risk factors, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019
  22. Bioinspired soft nanovesicles for site‐selective cancer imaging and targeted therapies
  23. Burden of non-communicable diseases among adolescents aged 10–24 years in the EU, 1990–2019: a systematic analysis of the Global Burden of Diseases Study 2019
  24. Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life Years for 29 Cancer Groups From 2010 to 2019
  25. Prodrug Polymeric Nanoconjugates Encapsulating Gold Nanoparticles for Enhanced X‐Ray Radiation Therapy in Breast Cancer
  26. The global burden of adolescent and young adult cancer in 2019: a systematic analysis for the Global Burden of Disease Study 2019
  27. Machine learning for next-generation nanotechnology in healthcare
  28. Child Mortality Trends and Targets: GBD 2019 Findings
  29. Nanomedicine-based strategies to target and modulate the tumor microenvironment
  30. Facts and Figures on Materials Science and Nanotechnology Progress and Investment
  31. Allosteric Antagonist Modulation of TRPV2 by Piperlongumine Impairs Glioblastoma Progression
  32. CRISPR Systems for COVID-19 Diagnosis
  33. Ultrahigh Penetration and Retention of Graphene Quantum Dot Mesoporous Silica Nanohybrids for Image Guided Tumor Regression
  34. Controlled delivery of gold nanoparticle-coupled miRNA therapeutics via an injectable self-healing hydrogel
  35. Revisiting gene delivery to the brain: silencing and editing
  36. “Swallowing the doctor”: an interview with João Conde about the future of nanomedicine
  37. Biomimetic cancer cell membrane-coated nanosystems as next-generation cancer therapies
  38. Why Go NANO on COVID-19 Pandemic?
  39. Above and Beyond Cancer Therapy: Translating Biomaterials into the Clinic
  40. Tetrazine Carbon Nanotubes for Pretargeted In Vivo “Click‐to‐Release” Bioorthogonal Tumour Imaging
  41. Nanotechnology-based disinfectants and sensors for SARS-CoV-2
  42. Liposomal nanotheranostics for multimode targeted in vivo bioimaging and near‐infrared light mediated cancer therapy
  43. Platinum-Triggered Bond-Cleavage of Pentynoyl Amide and N-Propargyl Handles for Drug-Activation
  44. Composite Hydrogels: Prolonged Local In Vivo Delivery of Stimuli‐Responsive Nanogels That Rapidly Release Doxorubicin in Triple‐Negative Breast Cancer Cells (Adv. Healthcare Mater. 4/2020)
  45. Prolonged Local In Vivo Delivery of Stimuli‐Responsive Nanogels That Rapidly Release Doxorubicin in Triple‐Negative Breast Cancer Cells
  46. Oral pH sensitive GNS@ab nanoprobes for targeted therapy of Helicobacter pylori without disturbance gut microbiome
  47. Gastric Parietal Cell and Intestinal Goblet Cell Secretion: a Novel Cell-Mediated In Vivo Metal Nanoparticle Metabolic Pathway Enhanced with Diarrhea Via Chinese Herbs
  48. Allosteric Antagonist Modulation of TRPV2 by Piperlongumine Impairs Glioblastoma Progression
  49. Cisplatin-Triggered Bioorthogonal Decaging of Amide Bonds for Targeted-Drug Activation in vivo
  50. Biopolymers for Antitumor Implantable Drug Delivery Systems: Recent Advances and Future Outlook
  51. Ferritin Nanocarrier Traverses the Blood Brain Barrier and Kills Glioma
  52. Nanoparticle-antagomiR based targeting of miR-31 to induce osterix and osteocalcin expression in mesenchymal stem cells
  53. Displaying biofunctionality on materials through templated self-assembly
  54. Handbook of Nanomaterials for Cancer Theranostics
  55. Fullerene: biomedical engineers get to revisit an old friend
  56. Smart NIR linear and nonlinear optical nanomaterials for cancer theranostics: Prospects in photomedicine
  57. Plasmonic gold nanoparticles for detection of fungi and human cutaneous fungal infections
  58. Designing Hydrogels for On-Demand Therapy
  59. 3D hydrogel scaffold doped with 2D graphene materials for biosensors and bioelectronics
  60. Empowering the Potential of Cell-Penetrating Peptides for Targeted Intracellular Delivery via Molecular Self-Assembly
  61. Gold nanostars for efficient in vitro and in vivo real-time SERS detection and drug delivery via plasmonic-tunable Raman/FTIR imaging
  62. Local microRNA delivery targets Palladin and prevents metastatic breast cancer
  63. Chiral Antioxidant-based Gold Nanoclusters Reprogram DNA Epigenetic Patterns
  64. Revisiting the ‘One Material Fits All’ Rule for Cancer Nanotherapy
  65. Revisiting the classification of NIR-absorbing/emitting nanomaterials for in vivo bioapplications
  66. Biomaterials for Abrogating Metastasis: Bridging the Gap between Basic and Translational Research
  67. Local triple-combination therapy results in tumour regression and prevents recurrence in a colon cancer model
  68. Gold nanoprisms as a hybrid in vivo cancer theranostic platform for in situ photoacoustic imaging, angiography, and localized hyperthermia
  69. Dual-Color Emissive Upconversion Nanocapsules for Differential Cancer Bioimaging In Vivo
  70. Editorial: Cancer Nanotheranostics: What Have We Learned So Far?
  71. Dual-sensitive hydrogel composite for local release and selective uptake of chemotherapy for the treatment of breast cancer
  72. RNAi nanomaterials targeting immune cells as an anti-tumor therapy: the missing link in cancer treatment?
  73. Self-assembled RNA-triple-helix hydrogel scaffold for microRNA modulation in the tumour microenvironment
  74. The Golden Age in Cancer Nanobiotechnology: Quo Vadis?
  75. Investigating the role of shape on the biological impact of gold nanoparticles in vitro
  76. Significance of the balance between intracellular glutathione and polyethylene glycol for successful release of small interfering RNA from gold nanoparticles
  77. Gold nanoparticle-siRNA mediated oncogene knockdown at RNA and protein level, with associated gene effects
  78. 15 years on siRNA delivery: Beyond the State-of-the-Art on inorganic nanoparticles for RNAi therapeutics
  79. Personalized Medicine: Personalizing Biomaterials for Precision Nanomedicine Considering the Local Tissue Microenvironment (Adv. Healthcare Mater. 11/2015)
  80. Bioresponsive antisense DNA gold nanobeacons as a hybrid in vivo theranostics platform for the inhibition of cancer cells and metastasis
  81. Dual Targeted Immunotherapy via In Vivo Delivery of Biohybrid RNAi-Peptide Nanoparticles to Tumor-Associated Macrophages and Cancer Cells
  82. POxylated Polyurea Dendrimers: Smart Core-Shell Vectors with IC50Lowering Capacity
  83. Personalizing Biomaterials for Precision Nanomedicine Considering the Local Tissue Microenvironment
  84. The next generation of smart gold nanobeacons: nanotheranostics is ready for prime time
  85. Implantable hydrogel embedded dark-gold nanoswitch as a theranostic probe to sense and overcome cancer multidrug resistance
  86. Are RNAi and miRNA therapeutics truly dead?
  87. RNAi-based glyconanoparticles trigger apoptotic pathways for in vitro and in vivo enhanced cancer-cell killing
  88. Target-responsive DNA/RNA nanomaterials for microRNA sensing and inhibition: The jack-of-all-trades in cancer nanotheranostics?
  89. A promising road with challenges: where are gold nanoparticles in translational research?
  90. Revisiting 30 years of biofunctionalization and surface chemistry of inorganic nanoparticles for nanomedicine
  91. Antibody–drug gold nanoantennas with Raman spectroscopic fingerprints for in vivo tumour theranostics
  92. Polyurea dendrimer for efficient cytosolic siRNA delivery
  93. Multifunctional Gold Nanocarriers for Cancer Theranostics: From Bench to Bedside and Back Again?
  94. In vivo tumor targeting via nanoparticle-mediated therapeutic siRNA coupled to inflammatory response in lung cancer mouse models
  95. Gold-nanobeacons for gene therapy: evaluation of genotoxicity, cell toxicity and proteome profiling analysis
  96. Gold-nanobeacons for simultaneous gene specific silencing and intracellular tracking of the silencing events
  97. Nanomaterials for reversion of multidrug resistance in cancer: a new hope for an old idea?
  98. Modification of plasmid DNA topology by ‘histone-mimetic’ gold nanoparticles
  99. Design of Multifunctional Gold Nanoparticles for In Vitro and In Vivo Gene Silencing
  100. Genotoxic effects of occupational exposure to lead and influence of polymorphisms in genes involved in lead toxicokinetics and in DNA repair
  101. Gold-nanobeacons for real-time monitoring of RNA synthesis
  102. Effect of PEG biofunctional spacers and TAT peptide on dsRNA loading on gold nanoparticles
  103. Noble Metal Nanoparticles for Biosensing Applications
  104. Nanophotonics for Molecular Diagnostics and Therapy Applications
  105. Alloy metal nanoparticles for multicolor cancer diagnostics
  106. In vitro transcription and translation inhibition via DNA functionalized gold nanoparticles
  107. Use of cyclodextrins as scavengers of inhibitory photo-products in light controlled in vitro synthesis of RNA
  108. RNA quantification using gold nanoprobes - application to cancer diagnostics
  109. Association of common variants in mismatch repair genes and breast cancer susceptibility: a multigene study